Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 78% Improvement Relative Risk Ventilation 52% Hospitalization 67% Recovery 59% c19ivm.org Lima-Morales et al. Ivermectin for COVID-19 LATE Is late treatment with ivermectin+combined treatments beneficial for COVID-19? Prospective study of 768 patients in Mexico Lower mortality (p=0.001) and hospitalization (p=0.001) Lima-Morales Favors ivermectin Favors control
Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico
Lima-Morales
Lima-Morales, Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic..,
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective trial of 768 COVID-19 outpatients in Mexico, 481 treated with ivermectin, AZ, montelukast, and aspirin, and 287 control patients with various treatments, showing significantly lower mortality and hospitalization, and significantly higher recovery at 14 days with treatment.
risk of death, 77.7% lower, RR 0.22, p < 0.001, treatment 15 of 481 (3.1%), control 52 of 287 (18.1%), NNT 6.7, adjusted per study, odds ratio converted to relative risk, multivariate.
risk of mechanical ventilation, 51.9% lower, RR 0.48, p = 0.15, treatment 8 of 434 (1.8%), control 11 of 287 (3.8%), NNT 50.
risk of hospitalization, 67.4% lower, RR 0.33, p < 0.001, treatment 44 of 481 (9.1%), control 89 of 287 (31.0%), NNT 4.6, adjusted per study, odds ratio converted to relative risk, multivariate.
risk of no recovery, 58.6% lower, RR 0.41, p < 0.001, treatment 75 of 481 (15.6%), control 118 of 287 (41.1%), NNT 3.9, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, recovery at day 14 after symptoms, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lima-Morales et al., 10 Feb 2021, prospective, Mexico, peer-reviewed, 9 authors, average treatment delay 7.2 days, dosage 12mg single dose, this trial uses multiple treatments in the treatment arm (combined with azithromycin, montelukast, and aspirin) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: International Journal of Infectious Diseases 105 (2021) 598–605 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico René Lima-Moralesa , Pablo Méndez-Hernándezb,c,j,* , Yvonne N. Floresc,d,e, Patricia Osorno-Romerob , Christian Ronal Sancho-Hernándezk , Elizabeth Cuecuecha-Rugeriob , Adrián Nava-Zamorab , Diego Rolando Hernández-Galdamezf , Daniela Karola Romo-Dueñasg,h , Jorge Salmeróni a Secretaría de Salud de Tlaxcala, Dirección General, Tlaxcala, Mexico Secretaría de Salud de Tlaxcala, Dirección de Atención Especializada a la Salud, Tlaxcala, Mexico Unidad de Investigación Epidemiológica y en Servicios de Salud, Delegación Morelos, Instituto Mexicano del Seguro Social, Blvd. Benito Juárez No. 31, Colonia Centro, Cuernavaca, Morelos, Mexico d UCLA Department of Health Policy and Management and Kaiser Permanente Center for Health Equity, Fielding School of Public Health, Los Angeles, CA, 90095, United States e UCLA Cancer Prevention and Control Research Center, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, United States f INCAP Research Center for the Prevention of Chronic Diseases (CIIPEC), Institute of Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala g Red Nacional de Registros de Cáncer, Guanajuato, Mexico h Instituto de Salud Pública del estado de Guanajuato (ISAPEG), Unidad de Vigilancia Epidemiológica Hospitalaria (UVEH), Hospital General León, Guanajuato, Mexico i Research Center on Policies, Population, and Health. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico j Universidad Autónoma de Tlaxcala, Facultad de Ciencias de la Salud, Tlaxcala, Mexico k Secretaría de Salud de Tlaxcala, Hospital General de Nativitas, Tlaxcala, Mexico b c A R T I C L E I N F O A B S T R A C T Article history: Received 20 November 2020 Received in revised form 2 February 2021 Accepted 4 February 2021 Objective: There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. This study aimed to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid ("TNR4" therapy) to prevent hospitalization and death among ambulatory COVID19 cases in Tlaxcala, Mexico. Design and methods: A comparative effectiveness study was performed among 768 confirmed SARS-CoV2 cases aged 18–80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment. Results: Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. The likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group. Conclusions: TNR4 therapy improved recovery and prevented the risk of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit